ArticleArchiv der Pharmazie2026
Fragment-Based Screening of Heterocyclic Electrophiles Identified Acrylamide Bioisoteres for Covalent KRas
Nikolett Péczka, Aaron Keeley, Péter Ábrányi-Balogh, Zoltán Orgován, László Petri, Emma K Grant, Chad Quinn, Soma Csanády, Ivan Randelovic, József Tóvári and 2 more
Abstract read
In one paragraphArticle in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Aaron KeeleyMedicinal Chemistry Research Group and National Drug Discovery and Development Laboratory, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
Péter Ábrányi-BaloghMedicinal Chemistry Research Group and National Drug Discovery and Development Laboratory, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.ORCID https://orcid.org/0000-0002-9284-5160 Zoltán OrgovánMedicinal Chemistry Research Group and National Drug Discovery and Development Laboratory, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
Emma K GrantGlaxoSmithKline, Stevenage, UK.
Chad QuinnGlaxoSmithKline, Stevenage, UK.
Soma CsanádyMedicinal Chemistry Research Group and National Drug Discovery and Development Laboratory, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
Ivan RandelovicDepartment of Experimental Pharmacology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary.
József TóváriDepartment of Experimental Pharmacology and the National Tumor Biology Laboratory, National Institute of Oncology, Budapest, Hungary.
Funding
HORIZON EUROPE Marie Sklodowska-Curie Actions Project 675899HORIZON EUROPE Marie Sklodowska-Curie Actions Project 956314Nemzeti Kutatási Fejlesztési és Innovációs Hivatal 2022-2.1.1-NL-2022-00010Nemzeti Kutatási Fejlesztési és Innovációs Hivatal K135150Nemzeti Kutatási Fejlesztési és Innovációs Hivatal K135335Nemzeti Kutatási Fejlesztési és Innovációs Hivatal RRF-2.3.1-21-2022-00015
6 · The paper itselfAbstract
Covalent fragment approaches gained increasing attention in medicinal chemistry. Our covalent heterocyclic fragment library (Covalent MiniFrags) consisting of five and six membered heterocycles was screened against the oncogenic target KRas
Indexed as
AcrylamideAntineoplastic AgentsHeterocyclic CompoundsProto-Oncogene Proteins p21(ras)BioisosterismCell Line, TumorCell SurvivalDose-Response Relationship, DrugHumansMolecular StructureStructure-Activity RelationshipAcrylamideAntineoplastic AgentsHeterocyclic CompoundsKRAS protein, humanProto-Oncogene Proteins p21(ras)electrophilefragment screenheterocycleKRastargeted covalent inhibitor
Identifiers
PMID42768907
PMCPMC13594984
What OpenQuestion holds
Textmetadata
Read underepoch 390